NCT01229215

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 143 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 60 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy.

Conditions

• Geographic Atrophy

Interventions

Type	Name	Description
DRUG	FCFD4514S	Repeating intravitreal injection
DRUG	sham	Repeating sham injection

Timeline

• Start date: 2011-02-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2010-10-27
• Last updated: 2016-11-02

Locations

36 sites across 2 countries: United States, Germany